Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
This study is testing if adding a second medication, bevacizumab, to the standard drug osimertinib can help control advanced lung cancer better than using osimertinib by itself. The goal is to see if this combination therapy can stop tumor growth for a longer period and improve survival for patients.
You may be eligible if you have advanced non-small cell lung cancer that has a specific genetic change called an EGFR mutation. The study is for patients whose cancer has spread or returned and who have not previously been treated with certain blood-vessel blocking drugs.
Participants will receive either osimertinib alone or the combination of osimertinib and bevacizumab. Throughout the study, you will have regular check-ups, including blood tests and imaging scans like CT or MRI scans to monitor how your body is responding to the treatment.
This study is currently recruiting new participants and is taking place at multiple locations in Anchorage, Alaska. Please speak with your healthcare provider to confirm if a location near you is currently open for enrollment.
- 1Researchers are comparing two treatment options to see which works best for your specific type of lung cancer.
- 2The medications work by both blocking cancer cell growth and cutting off the blood supply that tumors need to survive.
- 3Participation involves regular monitoring to ensure the treatment is being tracked accurately and safely.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.